OBI Pharma saw no growth in patent filings and highest growth of 0.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of OBI Pharma’s patent filings and grants. Buy the databook here.
OBI Pharma has been focused on protecting inventions in Australia(AU) with two publications in Q2 2024
The Australia(AU) Patent Office dominates the patent filings and grants with nearly 33% filings and 33% grants. The Australia(AU), World Intellectual Property Organization(WIPO), United States(US), and European Patent Office(EPO) patent Office are among the top ten patent offices where OBI Pharma is filings its patents. Among the top granted patent authorities, OBI Pharma has 33% of its grants in Australia(AU), 33% in European Patent Office(EPO) and 33% in Israel(IL).
Roche and Johnson & Johnson could be the strongest competitors for OBI Pharma
Patents related to cell & gene therapy and immuno-oncology lead OBI Pharma's portfolio
OBI Pharma has the highest number of patents in cell & gene therapy followed by, immuno-oncology and rare diseases. For cell & gene therapy, nearly 33% of patents were filed and no patents were granted in Q2 2024.
Metastatic breast cancer related patents lead OBI Pharma portfolio followed by breast cancer, and lung cancer
OBI Pharma has highest number of patents in metastatic breast cancer followed by breast cancer, lung cancer, bacterial infections, and diphtheria.
For comprehensive analysis of OBI Pharma's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.